Global Contraceptive Market are expected to grow at a CAGR of 5.5%, and contraceptive drugs and devices are expected to reach US$ 30.8 Billion by 2032.
According to the report, growing need of population control, increasing incidence of unwanted pregnancies and government’s initiatives drive the contraceptive market forward. It uses unique research methods to offer the most accurate analysis of the market.
Get Full Access @ https://www.futuremarketinsights.com/reports/contraceptives-market
It includes in-depth insights into the contraceptives market. Some of these are:
- The estimated value of the contraceptives market was at ~US$ 33,529 Mn in 2019. Through the course of the report’s forecast period, the market is exhibited to show a steady pace of growth.
- Regionally, North America dominates the contraceptives market globally.
- East Asia emerges as one of key markets owing to large population base, growing contraceptive awareness and initiatives taken by the respective country government.
- Female segment holds the most of the contraceptive market as compared to men.
- Key players are likely to focus on new product development in terms of drug device, to stay relevant in developed markets.
Some of the leading players operating in the contraceptives market are Bayer AGPfizer Inc., Janssen Global Services, LLC, Teva Pharmaceutical Industries Ltd., Merck Co., Inc., Mylan N.V., Allergan Plc, Reckitt Benckiser Group plc, Veru Inc., Medisafe Distribution Inc., Cooper Surgical, Inc., Mayer Laboratories, Inc., Pfizer, The Female Health Company and others. As a result of increasing competition, companies are focusing on expanding their product portfolio with new innovation. In addition to this, mergers and acquisition remains a popular strategy among market players. Companies intend to expand their regional footprint through strategic collaborations.
- As a part of government’s initiative, the government of India had launched a new contraceptive pill named ‘Shukhi 3rd Generation’ in Nov 2019.
- In Spet. 2019, Exeltis USA, Inc. had announced the Launch of Slynd(drospirenone) tablets, the First and only progestin-only pill providing pregnancy prevention with a 24-hour missed pill window
